Is all kidney disease in Diabetics "Diabetic Nephropathy"?

Welcome to AudioScholar. Today we're summarizing "Is all kidney disease in Diabetics "Diabetic Nephropathy"?", from NephJC. For practicing physicians, diabetic nephropathy is the leading cause of chronic kidney disease, or CKD, and end-stage kidney disease, or ESKD, worldwide. The classic teaching describes a predictable progression from hyperfiltration to proteinuria and eventual kidney failure. However, this classic picture is changing. It's now clear that many patients with diabetes develop non-diabetic kidney disease, or NDKD, which can have a very different prognosis and treatment plan. The challenge is that there are no universal guidelines on when to perform a kidney biopsy in a patient with diabetes to look for these alternative diagnoses. A recent large-scale study aimed to quantify the frequency of NDKD and identify clinical factors that should raise suspicion and prompt consideration for a biopsy.

The Study This was a large retrospective analysis of native kidney biopsies from patients with diabetes, conducted at Arkana Laboratories in the United States between 2001 and 2024. The final cohort included over 49,000 biopsies, making it the most comprehensive analysis of this question to date. The investigators categorized the biopsy findings into three groups: diabetic nephropathy alone, NDKD alone, or a combination of both. They then analyzed the clinical indications for the biopsy and linked the findings to long-term outcomes using the United States Renal Data Service database.

Results The first key finding was the remarkably high prevalence of non-diabetic kidney disease in this biopsied population. Overall, 58.8% of patients had some form of NDKD. This broke down into 35.9% having NDKD alone, and another 22.9% having NDKD superimposed on underlying diabetic nephropathy. Only 41.2% of biopsies showed diabetic nephropathy alone. The most common NDKD diagnoses included acute tubular injury, or ATI, acute interstitial nephritis, or AIN, and various forms of proliferative or crescentic glomerulonephritis.

The second major finding relates to the clinical predictors of NDKD. The study found that certain clinical presentations were strongly associated with finding a non-diabetic cause. The highest odds were for patients presenting with acute nephritic syndrome, which had an odds ratio of about 4 for finding NDKD. Other strong predictors included acute kidney injury, with an odds ratio of 3, and rapidly progressive renal failure, with an odds ratio of about 2.4. In contrast, clinical scenarios like heavy proteinuria or chronic kidney disease of unclear etiology were more likely to be diabetic nephropathy alone. The study also found that patients with earlier histologic stages of diabetic kidney disease, as defined by the Renal Pathology Society or RPS classification, were nearly twice as likely to have a concurrent NDKD diagnosis compared to those with advanced diabetic lesions.

Finally, the study highlighted the profound prognostic importance of making an accurate diagnosis. After linking biopsy results to long-term outcomes, the investigators found that patients with diabetic nephropathy alone had a significantly higher risk of progressing to end-stage kidney disease. The hazard ratio for progression was 2.56 times higher for those with diabetic nephropathy compared to those without it. This underscores that identifying a potentially treatable NDKD can dramatically alter a patient's long-term kidney survival.

The clinical relevance of this study is clear: kidney disease in patients with diabetes is far more varied than traditionally taught. Clinicians should maintain a high index of suspicion for NDKD, especially in patients presenting with atypical features. An acute presentation—such as acute kidney injury, an active urinary sediment, or rapidly progressive renal failure—should be a strong trigger to consider a kidney biopsy. While proteinuria is a hallmark of diabetic kidney disease, when it occurs in the context of these acute syndromes, a biopsy may reveal a treatable, non-diabetic pathology that carries a much better prognosis if identified and managed correctly.

As a caveat, this was a retrospective analysis of a biopsy cohort. This means it is subject to significant selection bias, as it only includes patients who were already deemed appropriate for a biopsy by their treating physician. The high prevalence of NDKD reflects this selected population, not the general population of all patients with diabetes and kidney disease.

That was a summary of Is all kidney disease in Diabetics "Diabetic Nephropathy"?, from NephJC. For the full piece, visit the original source. Until next time.